Dichlorphenamide
Active ingredient: Dichlorphenamide
In short: Dichlorphenamide tablets are indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
What is Dichlorphenamide used for?
Dichlorphenamide tablets are indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Dichlorphenamide dosage
Initiate dosing at 50 mg by mouth or twice daily. The dosage may be increased or decreased based on individual response, at weekly intervalsn (or sooner in case of adverse reaction). The minimum recommended total daily dosage is 50 mg, and the maximum recommended total daily dosage is 200 mg.
Primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants are a heterogeneous group of conditions, for which the response to dichlorphenamide may vary. Therefore, prescribers should evaluate the patient's response to dichlorphenamide after 2 months of treatment to decide whether dichlorphenamide tablets should be continued.
Baseline and periodic measurements of serum potassium and sodium bicarbonate during dichlorphenamide treatment is recommended .
How to take Dichlorphenamide — instructions & advice from the label
Worsening of Symptoms
Advise patients to notify their physician if they experience acute worsening of symptoms of periodic paralysis.
Hypersensitivity and Other Life-threatening Reactions
Inform patients that hypersensitivity and immune mediated reactions can occur with dichlorphenamide, and could be fatal. Advise patients to discontinue dichlorphenamide and notify their healthcare provider immediately if they develop a rash or signs and symptoms of anaphylaxis or other life-threatening reactions .
Drug Interactions
Instruct patients to notify their healthcare provider of all of the drugs and over-the-counter medications that they take and to not take aspirin or other salicylates without first discussing with their healthcare provider .
Metabolic Acidosis
Instruct patients to contact their healthcare provider immediately if they develop possible manifestations of metabolic acidosis (e.g., fast breathing, fatigue/tiredness, loss of appetite, or irregular heart beat or palpitations) .
Falls
Inform patients that dichlorphenamide can increase their risk of falls . …
Warnings & precautions
Do not take this medicine if: Dichlorphenamide is contraindicated in the following circumstances:
Hypersensitivity to dichlorphenamide or other sulfonamides
Concomitant use of dichlorphenamide and high dose aspirin
Severe pulmonary disease, limiting compensation to metabolic acidosis caused by dichlorphenamide
Hepatic insufficiency: dichlorphenamide may aggravate hepatic encephalopathy.
Fatalities associated with the administration of sulfonamides have occurred because of adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Pulmonary involvement can occur in isolation or as part of a systemic reaction.
Dichlorphenamide should be discontinued at the first appearance of skin rash or any sign of immune- mediated or other life-threatening adverse reaction.
Carbonic anhydrase inhibitors, including dichlorphenamide, can cause metabolic acidosis
, which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, the concomitant use of dichlorphenamide and high-dose aspirin is contraindicated.
Patients with concomitant use of dichlorphenamide and low-dose aspirin should be carefully monitored.
Dichlorphenamide increases potassium excretion and can cause hypokalemia. The risk of hypokalemia is greater when dichlorphenamide is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia
.
Baseline and periodic measurements of serum potassium during dichlorphenamide treatment is recommended. …
Dichlorphenamide side effects
The following serious adverse reactions are described elsewhere in labeling:
Hypersensitivity and Other Life-Threatening Reactions
Hypokalemia
Metabolic Acidosis
Falls

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a 9-week randomized controlled trial in adults with hyperkalemic or hypokalemic periodic paralysis (Study 1), the most common adverse reactions in patients treated with dichlorphenamide, with rates greater than placebo, were paresthesia, cognitive disorder, dysgeusia, and confusional state. The mean dose of dichlorphenamide was 94 mg/day in patients with hypokalemic periodic paralysis and 82 mg/day in patients with hyperkalemic periodic paralysis.
Table 1 lists the incidence of adverse reactions that occurred in ≥5% of patients treated with dichlorphenamide and more commonly than in patients treated with placebo in Study 1. …
Drug interactions
Carbonic anhydrase inhibitors, including dichlorphenamide, can cause metabolic acidosis
, which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, concomitant use of dichlorphenamide and high-dose aspirin is contraindicated. Patients with concomitant use of dichlorphenamide and low-dose aspirin should be carefully monitored
.
In vitro, dichlorphenamide is an inhibitor of OAT1 transporters. The concomitant administration of dichlorphenamide may increase the plasma exposures of OAT1 substrates. Use of dichlorphenamide with drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended
.
The risk of hypokalemia is greater with coadministration of dichlorphenamide and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline)
.
Coadministration of dichlorphenamide and other drugs that can cause metabolic acidosis may increase the severity of the acidosis
.
An
in vitro transporter study indicated that dichlorphenamide is a substrate of human transporters OAT1 and OAT3
. …
About this medicine
Dichlorphenamide tablets USP contain dichlorphenamide, an oral carbonic anhydrase inhibitor.
Dichlorphenamide USP, a dichlorinated benzenedisulfonamide, is known chemically as 4, 5–dichloro- 1,3-benzenedisulfonamide.
Its empirical formula is C
6H
6Cl
2N
2O
4S
2 and its structural formula is:
Dichlorphenamide USP is a white or practically white, crystalline powder with a molecular weight of 305.16. It is very slightly soluble in water but soluble in dilute solutions of alkali carbonate and hydroxide.
Dichlorphenamide tablets USP are supplied as tablets, for oral administration, each containing 50 mg dichlorphenamide USP. Inactive ingredients are lactose monohydrate, partially pregelatinized starch and magnesium stearate.
FDA Approved dissolution test specifications differ from USP.
How it works: Dichlorphenamide is a carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 64bf0c71-2113-47dc-8ce5-7fe535e558dc. Read the full official label on DailyMed.